Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mamoru Hashimoto

Showing results (161-170 of 195) with videos related to

Pageof 20
Sort By:
Translational Cancer Research|September 12, 2022
Prognostic factors in Japanese men with high-Gleason metastatic castration-resistant prostate cancerMitsuhisa Nishimoto, Kazutoshi Fujita, Yutaka Yamamoto, et al.
Psychogeriatrics : the Official Journal of the Japanese Psychogeriatric Society|August 12, 2025
Clinical and Neuroimaging Features of Tactile Hallucinations in Patients With Dementia With Lewy Bodies: A Cross-Sectional StudyKyosuke Kakeda, Hideki Kanemoto, Kenji Yoshiyama, et al.
The Prostate|January 31, 2025
Immunohistochemical Analysis of Androgen Receptor Expression Predicts the Prognosis of Metastatic Castration-Sensitive Prostate Cancer Patients Receiving Abiraterone AcetateMitsuhisa Nishimoto, Marco A De Velasco, Yutaka Yamamoto, et al.
Fluids and Barriers of the CNS|December 19, 2024
Association between choroid plexus volume and cognitive function in community-dwelling older adults without dementia: a population-based cross-sectional analysisYosuke Hidaka, Mamoru Hashimoto, Takashi Suehiro, et al.
Cancer Diagnosis & Prognosis|July 4, 2024
Gleason Pattern 5 May Be a Prognostic Factor in Radium-223 TreatmentMitsuhisa Nishimoto, Kazutoshi Fujita, Aritoshi Ri, et al.
The Journal of Urology|October 3, 2025
Diagnostic Accuracy of the Oncuria-Detect Multiplex Immunoassay in Detecting Upper Tract Urothelial CarcinomaKazutoshi Fujita, Makito Miyake, Mamoru Hashimoto, et al.
In Vivo (Athens, Greece)|April 28, 2025
Cancer-induced Pain Is Associated With Poor Overall Survival of Urothelial Carcinoma Patients Treated With Enfortumab VedotinMamoru Hashimoto, Ken Fukiage, Kosei Taniguchi, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|August 14, 2025
Comparison of Oncological Outcomes of Conventional Androgen Deprivation Therapy (ADT) and ADT Plus Androgen Receptor Signaling Inhibitor in Older Patients With Metastatic Castration-Sensitive Prostate CancerYutaka Yamamoto, Saizo Fujimoto, Mamoru Hashimoto, et al.
Translational Andrology and Urology|September 15, 2025
Upper urinary tract urothelial carcinoma patients show better overall response rate than bladder cancer patients during enfortumab vedotin treatment following pembrolizumabMamoru Hashimoto, Ken Fukiage, Kosei Taniguchi, et al.
International Journal of Clinical Oncology|October 1, 2024
Real-world outcomes in patients with metastatic castration-resistant prostate cancer beyond progression after upfront androgen receptor signaling inhibitorYutaka Yamamoto, Saizo Fujimoto, Mamoru Hashimoto, et al.
Pageof 20

Showing results (161-170 of 195) with videos related to

Sort By:
Pageof 20
Translational Cancer Research|September 12, 2022
Prognostic factors in Japanese men with high-Gleason metastatic castration-resistant prostate cancerMitsuhisa Nishimoto, Kazutoshi Fujita, Yutaka Yamamoto, et al.
Psychogeriatrics : the Official Journal of the Japanese Psychogeriatric Society|August 12, 2025
Clinical and Neuroimaging Features of Tactile Hallucinations in Patients With Dementia With Lewy Bodies: A Cross-Sectional StudyKyosuke Kakeda, Hideki Kanemoto, Kenji Yoshiyama, et al.
The Prostate|January 31, 2025
Immunohistochemical Analysis of Androgen Receptor Expression Predicts the Prognosis of Metastatic Castration-Sensitive Prostate Cancer Patients Receiving Abiraterone AcetateMitsuhisa Nishimoto, Marco A De Velasco, Yutaka Yamamoto, et al.
Fluids and Barriers of the CNS|December 19, 2024
Association between choroid plexus volume and cognitive function in community-dwelling older adults without dementia: a population-based cross-sectional analysisYosuke Hidaka, Mamoru Hashimoto, Takashi Suehiro, et al.
Cancer Diagnosis & Prognosis|July 4, 2024
Gleason Pattern 5 May Be a Prognostic Factor in Radium-223 TreatmentMitsuhisa Nishimoto, Kazutoshi Fujita, Aritoshi Ri, et al.
The Journal of Urology|October 3, 2025
Diagnostic Accuracy of the Oncuria-Detect Multiplex Immunoassay in Detecting Upper Tract Urothelial CarcinomaKazutoshi Fujita, Makito Miyake, Mamoru Hashimoto, et al.
In Vivo (Athens, Greece)|April 28, 2025
Cancer-induced Pain Is Associated With Poor Overall Survival of Urothelial Carcinoma Patients Treated With Enfortumab VedotinMamoru Hashimoto, Ken Fukiage, Kosei Taniguchi, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|August 14, 2025
Comparison of Oncological Outcomes of Conventional Androgen Deprivation Therapy (ADT) and ADT Plus Androgen Receptor Signaling Inhibitor in Older Patients With Metastatic Castration-Sensitive Prostate CancerYutaka Yamamoto, Saizo Fujimoto, Mamoru Hashimoto, et al.
Translational Andrology and Urology|September 15, 2025
Upper urinary tract urothelial carcinoma patients show better overall response rate than bladder cancer patients during enfortumab vedotin treatment following pembrolizumabMamoru Hashimoto, Ken Fukiage, Kosei Taniguchi, et al.
International Journal of Clinical Oncology|October 1, 2024
Real-world outcomes in patients with metastatic castration-resistant prostate cancer beyond progression after upfront androgen receptor signaling inhibitorYutaka Yamamoto, Saizo Fujimoto, Mamoru Hashimoto, et al.
Pageof 20